These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 15388420)
61. Synthesis and anti-HIV activity of aryl-2-[(4-cyanophenyl)amino]-4-pyrimidinone hydrazones as potent non-nucleoside reverse transcriptase inhibitors. Ma XD; Yang SQ; Gu SX; He QQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C ChemMedChem; 2011 Dec; 6(12):2225-32. PubMed ID: 21990112 [TBL] [Abstract][Full Text] [Related]
62. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Van Herrewege Y; Michiels J; Van Roey J; Fransen K; Kestens L; Balzarini J; Lewi P; Vanham G; Janssen P Antimicrob Agents Chemother; 2004 Jan; 48(1):337-9. PubMed ID: 14693562 [TBL] [Abstract][Full Text] [Related]
63. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. Wainberg MA J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S2-7. PubMed ID: 14562852 [TBL] [Abstract][Full Text] [Related]
64. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Calza L; Manfredi R; Chiodo F Int J Antimicrob Agents; 2003 Aug; 22(2):89-99. PubMed ID: 12927947 [TBL] [Abstract][Full Text] [Related]
65. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. Di Fabio S; Van Roey J; Giannini G; van den Mooter G; Spada M; Binelli A; Pirillo MF; Germinario E; Belardelli F; de Bethune MP; Vella S AIDS; 2003 Jul; 17(11):1597-604. PubMed ID: 12853741 [TBL] [Abstract][Full Text] [Related]
66. Metabolic effects of protease inhibitor therapy. Bernasconi E AIDS Read; 1999 Jul; 9(4):254-6, 259-60, 266-9. PubMed ID: 12737115 [TBL] [Abstract][Full Text] [Related]
67. Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission. Van Herrewege Y; Penne L; Vereecken C; Fransen K; van der Groen G; Kestens L; Balzarini J; Vanham G AIDS Res Hum Retroviruses; 2002 Oct; 18(15):1091-102. PubMed ID: 12396448 [TBL] [Abstract][Full Text] [Related]
68. An introduction to nucleoside and nucleotide analogues. Squires KE Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469 [TBL] [Abstract][Full Text] [Related]
69. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Ludovici DW; De Corte BL; Kukla MJ; Ye H; Ho CY; Lichtenstein MA; Kavash RW; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Heeres J; Koymans LM; de Jonge MR; Van Aken KJ; Daeyaert FF; Das K; Arnold E; Janssen PA Bioorg Med Chem Lett; 2001 Sep; 11(17):2235-9. PubMed ID: 11527705 [TBL] [Abstract][Full Text] [Related]
70. Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. Ludovici DW; Kavash RW; Kukla MJ; Ho CY; Ye H; De Corte BL; Andries K; de Béthune MP; Azijn H; Pauwels R; Moereels HE; Heeres J; Koymans LM; de Jonge MR; Van Aken KJ; Daeyaert FF; Lewi PJ; Das K; Arnold E; Janssen PA Bioorg Med Chem Lett; 2001 Sep; 11(17):2229-34. PubMed ID: 11527704 [TBL] [Abstract][Full Text] [Related]
71. Modeling HIV transfer between dendritic cells and T cells: importance of HIV phenotype, dendritic cell-T cell contact and T-cell activation. Vanham G; Penne L; Allemeersch H; Kestens L; Willems B; van der Groen G; Jeang KT; Toossi Z; Rich E AIDS; 2000 Oct; 14(15):2299-311. PubMed ID: 11089618 [TBL] [Abstract][Full Text] [Related]
73. Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options. Kaufmann GR; Cooper DA Curr Opin Microbiol; 2000 Oct; 3(5):508-14. PubMed ID: 11050451 [TBL] [Abstract][Full Text] [Related]
74. Dendritic cells, exposed to primary, mixed phenotype HIV-1 isolates preferentially, but not exclusively, replicate CCR5-using clones. Vanham G; Davis D; Willems B; Penne L; Kestens L; Janssens W; van der Groen G AIDS; 2000 Aug; 14(12):1874-6. PubMed ID: 10985336 [No Abstract] [Full Text] [Related]
75. Current status and future issues in the treatment of HIV-1 infection. Matsushita S Int J Hematol; 2000 Jul; 72(1):20-7. PubMed ID: 10979204 [TBL] [Abstract][Full Text] [Related]
76. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. Hu J; Gardner MB; Miller CJ J Virol; 2000 Jul; 74(13):6087-95. PubMed ID: 10846092 [TBL] [Abstract][Full Text] [Related]
77. PCR-Based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells. Christopherson C; Kidane Y; Conway B; Krowka J; Sheppard H; Kwok S J Clin Microbiol; 2000 Feb; 38(2):630-4. PubMed ID: 10655358 [TBL] [Abstract][Full Text] [Related]
78. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142 [TBL] [Abstract][Full Text] [Related]
79. Dendritic cells route human immunodeficiency virus to lymph nodes after vaginal or intravenous administration to mice. Masurier C; Salomon B; Guettari N; Pioche C; Lachapelle F; Guigon M; Klatzmann D J Virol; 1998 Oct; 72(10):7822-9. PubMed ID: 9733818 [TBL] [Abstract][Full Text] [Related]